Medaysis
Enable Innovation

DATA SHEET

Mouse Anti-CD86/Dendritic Cells Maturation Marker [SPM600]: MC0031, MC0031RTU7

Intended Use: For Research Use Only

Description: Recognizes a protein of 70kDa, which is identified as CD86. CD86 is a type I transmembrane glycoprotein and a member of the immunoglobulin superfamily of cell surface receptors. It is expressed at high levels on resting peripheral monocytes and dendritic cells and at very low density on resting B and T lymphocytes. CD86 expression is rapidly upregulated by B cell specific stimuli with peak expression at 18 to 42 hours after stimulation. CD86, along with CD80/B71, is an important accessory molecule in T cell co-stimulation via its interaction with CD28 and CD152/CTLA4. Since CD86 has rapid kinetics of induction, it is believed to be the major CD28 ligand expressed early in the immune response. It is also found on malignant Hodgkin and Reed Sternberg (HRS) cells in Hodgkin's disease.

Specifications:

Clone:	SPM600
Source:	Mouse
Isotype:	IgG1k
Reactivity:	Human, mouse, rat
Localization:	Membrane
Formulation:	Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC, Flow Cyt., ICC/IF, WB

Package:

Description	Catalog No.	Size
CD86/Dendritic Cells Maturation Marker Concentrated	MC0031	1 ml
CD86/Dendritic Cells Maturation Marker Prediluted	MC0031RTU7	7 ml

IHC Procedure*:

Positive Control Tissue:	293T or Jukat cells. Monocytes and dendritic cells, activated T, B and natural killer cells in lymph node or tonsil
Concentrated Dilution:	25-100
Pretreatment:	EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human melanoma stained with anti-CD86 using DAB

References

1. A Potential Inhibitory Profile of Liver CD68+ Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression. Said EA, et al. PLoS One. 2016 Apr 11;11(4):e0153191, 2016.
2. Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells. Bak SP, et al. J Immunol. Aug 15;189(4):1708-16, 2012.
3. Expression and distribution of S-100, CD83, and costimulatory molecules (CD80 and CD86) in tissues of thyroid papillary carcinoma. Xu WC, et al. Cancer Invest. May;29(4):286-92, 2011.

Orders: customercare@medaysis.com Support: techsupport@medaysis.com Tel: 510-509-3153 www.medaysis.com